Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2025)

Historic Revenue for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to $12.8 million.

  • Monte Rosa Therapeutics' Revenue rose 3854.17% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.5 million, marking a year-over-year increase of 111227.38%. This contributed to the annual value of $75.6 million for FY2024, which is N/A changed from last year.
  • Monte Rosa Therapeutics' Revenue amounted to $12.8 million in Q3 2025, which was up 3854.17% from $23.2 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Revenue high stood at $84.9 million for Q1 2025, and its period low was $1.1 million during Q1 2024.